LinkedIn Image

Examining Successes and Seeking New Strategies in Pediatric Acute Lymphoblastic Leukemia

Meeting Overview

This symposium, to be held at the International BFM Study Group (I-BFM) Conference, will update attendees on recent data that have led to improved acute lymphoblastic leukemia (ALL) prognosis and treatment decision-making at every stage of therapy. Pediatric ALL thought leaders will share new insights into distinguishing between asparaginase hypersensitivity reactions and “allergic-like” reactions during first-line treatment, optimal techniques for measuring minimal residual disease (MRD) after initial therapy, and novel treatment strategies for relapsed ALL. Participants will be provided with an update on practice-changing data in a practical and interactive format, fostering discussion and impacting clinical outcomes for patients with ALL.


17.30 Welcome and introduction
Shai Izraeli, MD
Are you an ALL guru?
Shai Izraeli, MD
17.35 There is only one first time: Making the most of initial therapy for pediatric ALL
Ajay Vora, MD, FRCP, FRCPath
17.50 How do you measure success in ALL?: Assessment of MRD
Martin Schrappe, MD, PhD
18.05 Strategic decisions for relapsed ALL: How and when to incorporate novel agents
Shai Izraeli, MD
18.20 Clinical vignettes
Shai Izraeli, MD
18.28 Conclusion and prIME Points
Shai Izraeli, MD
18.30 Reception


  • Shai Izraeli, MDSheba Medical Center
    Tel Aviv University
    Tel Aviv, Israel
  • Martin Schrappe, MD, PhDUniversity Medical Center Schleswig-Holstein
    Kiel, Germany
  • Ajay Vora, MD, FRCP, FRCPathGreat Ormond Street Hospital
    London, United Kingdom
    University of Sheffield
    Sheffield, United Kingdom

Target Audience

This educational activity is specifically designed to meet the needs of practicing hematologists, medical oncologists, pediatric oncologists, and other healthcare providers involved in the management of patients with pediatric ALL and the consequences of this disease.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Select an appropriate first-line treatment strategy for pediatric patients with ALL based on recent clinical trial data and expert recommendations, including considerations for “pediatric-inspired” therapy for adolescent patients
  • Describe the importance of eliminating minimal residual disease and the role it plays in treatment selection throughout the management of ALL
  • Identify an effective treatment approach for patients with relapsed/refractory ALL, including considerations for reinduction, prognostic factors, and incorporation of emerging therapies
Register Now

Date and Location

Tuesday, 9 May 2017
17.30 – 18.30

Ballroom A+B
Dan Jerusalem Hotel
32 Lehi St
Jerusalem, Israel

Printed Materials

Printed Materials


This activity is provided by prIME Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.



This educational activity is supported by a grant from Shire.

Sunshine Act and EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.